Navigation Links
Renal denervation gives better outcomes than drugs in advanced heart failure
Date:8/27/2012

Munich, Germany August 27 2012: Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Milo Tborsk from the University Hospital Olomouc.

Renal denervation does not involve any pharmacological treatment. It is a multiple application of radiofrequency energy using a thin catheter via the femoral artery and a long-term "denervation" of the sympathetic nerves around the renal arteries. "This is done to prevent an increased excretion of the substances leading to heart failure," said Dr Tborsk.

The aim of this pilot study was to compare the outcomes of patients with advanced heart failure receiving standard pharmacological treatment or renal denervation. Over the period of one year, 26 patients were treated with renal denervation and standard pharmacotherapy and 25 patients received standard drug treatment with beta-blockers, ACE inhibitors or ARBs and diuretics.

After one year contractile function of the left side of the heart improved in patients treated with renal denervation from 2512% to 3114% (p<0.01).

There was no change in contractile function of the left side of the heart in patients who received standard drug treatment. "The improvement of the contractile function of the left side of the heart by more than 10% in patients after renal denervation was a surprise," said Dr Tborsk. "This parameter has practically not changed in patients treated by the classic drugs. The difference in response might be explained by a continuous decrease of the renal sympathetic activity in the complex pathophysiology of heart failure."

During the one year follow-up, 8 patients treated with renal denervation were hospitalized due to heart failure compared to 18 patients treated with standard drug therapy. Dr Tborsk said: "Twice the number of patients treated by classic pharmacological therapy were taken to hospital due to heart failure."

The disadvantage of denervation, as with any invasive treatment, is the potential for subsequent complications. "We have registered two complications the formation of a fistula by the artery and the vein in the place of puncture and the formation of thrombi despite all safety measures being adhered to," said Dr Tborsk. "We have successfully removed both complications by a surgical revision and thromboaspiration."

The findings indicate that renal denervation may be a non-pharmacological alternative for the treatment of patients with advanced heart failure and may help stabilise the disease. "Renal denervation is particularly suited for patients without an extensive scar after myocardial infarction and whose heart rate increases when they are treated with the maximum tolerated dose of beta-blockers," added Dr Tborsk.

He concluded: "The long-term effects of renal denervation should be confirmed in a large international randomised study."


'/>"/>

Contact: ESC Press Office
press@escardio.org
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Broken heart syndrome protects the heart from adrenaline overload
2. Newborn Screening May Miss Adrenal-Gland Disorder
3. Human Airways Brush Mechanism Gives Clues to Lung Diseases
4. FDA Gives Nod to First Drug for Diabetic Eye Disease
5. FDA Gives Nod to New Breast Cancer Drug
6. Study Gives First Evidence That Adult Human Lungs Can Regrow
7. OC Firm Gives Back to Young Athletes
8. Aurora Dentist Gives Patients Big Savings With Teeth in a Day Implants
9. Killer stainless steel: New process gives icon of cleanliness antibacterial coating
10. Amazon Tribe Gives Clues to Heart-Healthy Lifestyles
11. FDA Panel Gives Blessing to New Weight-Loss Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology: